STRATA Skin Sciences Faces Listing Rule Issues

TL;DR

STRATA Skin Sciences might be in trouble with NASDAQ listing rules.

AI Summary

STRATA Skin Sciences, Inc. filed an 8-K on August 22, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event reported on August 19, 2025. The company, formerly known as MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC, is incorporated in Delaware and headquartered in Horsham, PA.

Why It Matters

This filing indicates potential issues with STRATA Skin Sciences' continued listing on its exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial stability.

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• MELA SCIENCES, INC. (company) — Former company name
• ELECTRO OPTICAL SCIENCES INC (company) — Former company name
• NASDAQ (company) — Exchange
• August 19, 2025 (date) — Earliest event date
• August 22, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0,001 — (s) on which registered Common Stock, $0,001 par value per share SSKN The Nasdaq
• $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"

Filing Documents

• ef20054303_8k.htm (8-K) — 31KB
• 0001140361-25-032373.txt ( ) — 158KB
• sskn-20250819.xsd (EX-101.SCH) — 4KB
• sskn-20250819_lab.xml (EX-101.LAB) — 21KB
• sskn-20250819_pre.xml (EX-101.PRE) — 16KB
• ef20054303_8k_htm.xml (XML) — 4KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 19, 2025, Strata Skin Sciences, Inc. (the "Company") received notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"). In the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders' equity below the Stockholders' Equity Requirement for continued listing, and as of the date of this report, the Company does not meet any alternative Nasdaq compliance standards relating to the market value of listed securities or net income from continuing operations. The Notice has no immediate effect on the listing of the Company's common stock and the Company's common stock continues to trade on The Nasdaq Capital Market under the symbol "SSKN," subject to the Company's compliance with the other continued listing requirements. Pursuant to the Notice, Nasdaq has given the Company 45 calendar days, or until October 3, 2025, to submit to Nasdaq a plan to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice to evidence compliance. The Company is currently evaluating various courses of action to regain compliance and plans to timely submit its plan to Nasdaq to regain compliance with the Stockholders' Equity Requirement. There can be no assurance that the Company's plan will be accepted or that if it is, the Company will be able to regain compliance. If the Company's plan to regain compliance is not accepted, or if it is and the Company does not regain compliance within 180 days from the date of N

Forward-Looking Statements

Forward-Looking Statements Certain statements contained in this Current Report on Form 8-K are not historical facts and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. This information includes, without limitation, statements concerning the Company's intention or ability to regain compliance with the applicable Nasdaq listing requirements, the Company's intention to appeal the Nasdaq staff's determination, the Company's expectation that a request for a Panel hearing will stay the suspension of the Company's securities pending the Panel's decision, the timing and nature of any hearing before the Panel, the outcome of the Panel's review of any Company appeal of the Nasdaq staff's determination, and any courses of action to regain compliance with the applicable Nasdaq listing requirements. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These and other risks are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of its annual report on Form 10-K for the fiscal year ended December 31, 2024, and any risks that may be contained in any subsequent filings that the Company makes with the SEC. The Company undertakes no obligation to publicly update any forward-looking

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Dated: August 22, 2025 By: /s/ John Gillings John Gillings Chief Accounting Officer

View Full Filing

View this 8-K filing on SEC EDGAR